These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 15095753)

  • 21. Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure.
    Meredith PA
    Curr Med Res Opin; 2007 Jul; 23(7):1693-705. PubMed ID: 17588300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Candesartan reduces the risk of mortality and recurrence of chronic heart failure. Important results from the CHARM study].
    Persson H; Swedberg K
    Lakartidningen; 2004 Feb; 101(9):764-6. PubMed ID: 15045839
    [No Abstract]   [Full Text] [Related]  

  • 23. VALIANT trial results support use of valsartan in acute myocardial infarction.
    Cardiovasc J S Afr; 2004; 15(1):45, 47. PubMed ID: 15095754
    [No Abstract]   [Full Text] [Related]  

  • 24. Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension.
    Zanchetti A; Omboni S; Di Biagio C
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S57-9. PubMed ID: 9331009
    [No Abstract]   [Full Text] [Related]  

  • 25. [Angiotensin receptor antagonist for therapy of patients with hypertension].
    Rakugi H; Ogihara T
    Nihon Rinsho; 1997 Aug; 55(8):2075-80. PubMed ID: 9284426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.
    Hoy SM; Keating GM
    Am J Cardiovasc Drugs; 2010; 10(5):335-42. PubMed ID: 20860416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The CHARM program: the effects of candesartan for the management of patients with chronic heart failure.
    McKelvie RS
    Expert Rev Cardiovasc Ther; 2009 Jan; 7(1):9-16. PubMed ID: 19105762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Candesartan: widening indications for this angiotensin II receptor blocker?
    Mendis B; Page SR
    Expert Opin Pharmacother; 2009 Aug; 10(12):1995-2007. PubMed ID: 19563275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    McMurray JJ; Young JB; Dunlap ME; Granger CB; Hainer J; Michelson EL; Earle S; Olofsson B; Ostergren J; Yusuf S; Swedberg K; Pfeffer MA;
    Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effect of angiotensin II receptor antagonist on heart failure].
    Matsumori A
    Nihon Rinsho; 2004 Jan; 62(1):203-10. PubMed ID: 14737854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
    Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Pocock S; Wang D; Wilhelmsen L; Hennekens CH
    Am Heart J; 2005 May; 149(5):939-43. PubMed ID: 15894981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving prognosis in hypertension: exploring the benefits of angiotensin II type 1 receptor blockade.
    Ruilope L
    Blood Press Suppl; 2000; 1():31-5. PubMed ID: 11059634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The CHARM programme.
    Pechlaner C
    Lancet; 2003 Nov; 362(9396):1675-6; author reply 1678-9. PubMed ID: 14630453
    [No Abstract]   [Full Text] [Related]  

  • 36. [ACE inhibitors or AT1 receptor antagonists?].
    Riegger GA
    Dtsch Med Wochenschr; 1999 Sep; 124 Suppl 2():S37-9. PubMed ID: 10535045
    [No Abstract]   [Full Text] [Related]  

  • 37. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
    Sever PS
    Blood Press Suppl; 2000; 1():19-22. PubMed ID: 11059631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical profiles of new angiotensin II receptor blockers: telmisartan, olmesartan medoxomil, and irbesartan].
    Ishii M
    Nihon Rinsho; 2004 Jan; 62(1):193-202. PubMed ID: 14737853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of candesartan cilexetil in special patient groups.
    Trenkwalder P
    Blood Press Suppl; 2000; 1():27-30. PubMed ID: 11059633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preserving target-organ function with candesartan cilexetil in patients with hypertension.
    Zannad F
    Blood Press Suppl; 2000; 1():36-9. PubMed ID: 11059635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.